Bausch Health Companies Inc. (NYSE:BHC) shares traded 10.20% higher at $9.29 on Wall Street last session.
In accordance with the data, 8 analysts cover Bausch Health Companies Inc. (NYSE:BHC). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $12.00 and a low of $6.00, we find $8.00. Given the previous closing price of $8.43, this indicates a potential downside of -5.1 percent. BHC stock price is now 23.96% away from the 50-day moving average and 24.05% away from the 200-day moving average. The market capitalization of the company currently stands at $3.37B.
It has been rated a hold by 6 analysts and a buy by 1. Brokers who have rated the stock have averaged $8.50 as their price target over the next twelve months.
In other news, Carson Seana, EVP, General Counsel sold 292 shares of the company’s stock on Feb 28. The stock was sold for $2,721 at an average price of $9.32. Upon completion of the transaction, the EVP, General Counsel now directly owns 359,185 shares in the company, valued at $3.34 million. A total of 2.30% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in BHC stock. In total, there are 367 active investors with 66.80% ownership of the company’s stock.
Bausch Health Companies Inc. (NYSE: BHC) opened at $8.40 on Monday. During the past 12 months, Bausch Health Companies Inc. has had a low of $4.00 and a high of $10.23. The fifty day moving average price for BHC is $7.53 and a two-hundred day moving average price translates $7.50 for the stock.
The latest earnings results from Bausch Health Companies Inc. (NYSE: BHC) was released for Mar, 2023. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at $0.52, missing analysts’ expectations of $0.72 by -0.2. This compares to -$0.18 EPS in the same period last year. The net profit margin was -4.40% and return on equity was 52.70% for BHC. The company reported revenue of $1.94 billion for the quarter, compared to $1.92 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 1.36 percent. For the current quarter, analysts expect BHC to generate $2.04B in revenue.
Moreover, the firm recently paid out its quarterly dividend on 12/22/2010. Investors who held shares on 11/15/2010 were paid a $1.00 dividend.
Bausch Health Companies Inc.(BHC) Company Profile
Bausch Health Companies Inc. operates as a diversified pharmaceutical company. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. was incorporated in 2013 and is headquartered in Laval, Canada.
